(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 December 2014 - Actelion Ltd (SIX: ATLN) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for selexipag (Uptravi®) for the treatment of patients with pulmonary arterial hypertension (PAH). Selexipag, the first selective oral IP prostacyclin receptor agonist, was studied in the pivotal Phase III GRIPHON study in 1,156 patients with pulmonary arterial hypertension (PAH). As reported in June 2014, the study demonstrated that selexipag decreased the risk of a morbidity/mortality event versus placebo by 39% (p5%) on selexipag compared to placebo are headache,...
↧